SiRNA targeting of PRDX3 enhances cisplatin-induced apoptosis in ovarian cancer cells through the suppression of the NF-κB signaling pathway

Molecular Medicine Reports

Volumn 7, Issue 5, 2013, Pages 1688-1694

  Duan, Jie ^a   Lang, Yan ^a   Song, Chengwen ^b   Xiong, Jun ^a   Wang, Yan ^a   Yan, Yang ^a  

^a Maternal and Child Health Hospital of Hubei Province   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Cisplatin; NF B; Ovarian cancer; Peroxiredoxins; PRDX3

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXIREDOXIN 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVARY CANCER;

ADULT; AGED; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; ENZYME ACTIVATION; FEMALE; HUMANS; MICE; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; OVARIAN NEOPLASMS; PEROXIREDOXIN III; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 84876002151     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1370     Document Type: Article

References (25)

1. Wolf JK and Jenkins AD: Gene therapy for ovarian cancer (Review). Int J Oncol 21: 461-468, 2002.
2. Felix AS, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL and Linkov F: Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer 21: 877-884, 2011.
3. Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC and Fasih N: Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics 31: 625-646, 2011.
4. Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366: 1382-1392, 2012.
5. Stańczyk M, Gromadzińska J and Wasowicz W: Roles of reactive oxygen species and selected antioxidants in regulation of cellular metabolism. Int J Occup Med Environ Health 18: 15-26, 2005.
6. Okai Y, Sato EF, Higashi-Okai K and Inoue M: Potentiating effect of an endocrine disruptor, paranonylphenol, on the generation of reactive oxygen species (ROS) in human venous blood -association with the activation of signal transduction pathway. J UOEH 29: 221-233, 2007.
7. Moon HJ, Ko WK, Han SW, Kim DS, Hwang YS, Park HK and Kwon IK: Antioxidants, like coenzyme Q10, selenite, and curcumin, inhibited osteoclast differentiation by suppressing reactive oxygen species generation. Biochem Biophys Res Commun 418: 247-253, 2012.
8. Avni R, Cohen B and Neeman M: Hypoxic stress and cancer: imaging the axis of evil in tumor metastasis. NMR Biomed 24: 569-581, 2011.
9. Morita M, Yano S, Yamaguchi T, Yamauchi M and Sugimoto T: Phenylacetic acid stimulates reactive oxygen species generation and tumor necrosis factor-α secretion in vascular endothelial cells. Ther Apher Dial 15: 147-150, 2011.
10. Pak JH, Choi WH, Lee HM, et al: Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest 29: 21-28, 2011.
11. Lowther WT and Haynes AC: Reduction of cysteine sulfinic acid in eukaryotic, typical 2-Cys peroxiredoxins by sulfiredoxin. Antioxid Redox Signal 15: 99-109, 2011.
12. Aran M, Ferrero DS, Pagano E and Wolosiuk RA: Typical 2-Cys peroxiredoxins -modulation by covalent transformations and noncovalent interactions. FEBS J 276: 2478-2493, 2009.
13. Rhee SG and Woo HA: Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H2O2, and protein chaperones. Antioxid Redox Signal 15: 781-794, 2011.
14. Lin H, Lu JP, Laflamme P, et al: Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: A mechanistic model supporting prevention strategies. Int J Oncol 37: 761-766, 2010.
15. Flohé L, Budde H and Hofmann B: Peroxiredoxins in antioxidant defense and redox regulation. Biofactors 19: 3-10, 2003.
16. Qiao B, Wang J, Xie J, Niu Y, Ye S, Wan Q and Ye Q: Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med 29: 832-840, 2012.
17. Kim YS, Lee HL, Lee KB, et al: Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. Korean J Intern Med 26: 304-313, 2011.
18. Basu A, Banerjee H, Rojas H, et al: Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate 71: 755-765, 2011.
19. Dai Z, Yin J, He H, et al: Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics 10: 3789-3799, 2010.
20. Lee S, Kwon H, Jeong K and Pak Y: Regulation of cancer cell proliferation by caveolin-2 down-regulation and re-expression. Int J Oncol 38: 1395-1402, 2011.
21. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
22. Bookman MA: Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21 (10 Suppl): 149s-167s, 2003.
23. Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J and Cheng X: Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 64: 4577-4584, 2004.
24. Oiso S, Ikeda R, Nakamura K, Takeda Y, Akiyama S and Kariyazono H: Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells. Oncol Rep 28: 27-32, 2012.
25. Sethi G, Sung B and Aggarwal BB: Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 233: 21-31, 2008.